Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,675 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants.
Rio-Machin A, Vulliamy T, Hug N, Walne A, Tawana K, Cardoso S, Ellison A, Pontikos N, Wang J, Tummala H, Al Seraihi AFH, Alnajar J, Bewicke-Copley F, Armes H, Barnett M, Bloor A, Bödör C, Bowen D, Fenaux P, Green A, Hallahan A, Hjorth-Hansen H, Hossain U, Killick S, Lawson S, Layton M, Male AM, Marsh J, Mehta P, Mous R, Nomdedéu JF, Owen C, Pavlu J, Payne EM, Protheroe RE, Preudhomme C, Pujol-Moix N, Renneville A, Russell N, Saggar A, Sciuccati G, Taussig D, Toze CL, Uyttebroeck A, Vandenberghe P, Schlegelberger B, Ripperger T, Steinemann D, Wu J, Mason J, Page P, Akiki S, Reay K, Cavenagh JD, Plagnol V, Caceres JF, Fitzgibbon J, Dokal I. Rio-Machin A, et al. Among authors: mehta p. Nat Commun. 2020 Feb 25;11(1):1044. doi: 10.1038/s41467-020-14829-5. Nat Commun. 2020. PMID: 32098966 Free PMC article.
Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
Dillon R, Hills R, Freeman S, Potter N, Jovanovic J, Ivey A, Kanda AS, Runglall M, Foot N, Valganon M, Khwaja A, Cavenagh J, Smith M, Ommen HB, Overgaard UM, Dennis M, Knapper S, Kaur H, Taussig D, Mehta P, Raj K, Novitzky-Basso I, Nikolousis E, Danby R, Krishnamurthy P, Hill K, Finnegan D, Alimam S, Hurst E, Johnson P, Khan A, Salim R, Craddock C, Spearing R, Gilkes A, Gale R, Burnett A, Russell NH, Grimwade D. Dillon R, et al. Among authors: mehta p. Blood. 2020 Feb 27;135(9):680-688. doi: 10.1182/blood.2019002959. Blood. 2020. PMID: 31932839 Free PMC article. Clinical Trial.
A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia.
Coats T, Bean D, Basset A, Sirkis T, Brammeld J, Johnson S, Thomas I, Gilkes A, Raj K, Dennis M, Knapper S, Mehta P, Khwaja A, Hunter H, Tauro S, Bowen D, Jones G, Dobson R, Russell N, Dillon R. Coats T, et al. Among authors: mehta p. Br J Haematol. 2022 Mar;196(6):1337-1343. doi: 10.1111/bjh.18013. Epub 2021 Dec 26. Br J Haematol. 2022. PMID: 34957541
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.
Othman J, Wilhelm-Benartzi C, Dillon R, Knapper S, Freeman SD, Batten LM, Canham J, Hinson EL, Wych J, Betteridge S, Villiers W, Kleeman M, Gilkes A, Potter N, Overgaard UM, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Dennis M, Russell NH. Othman J, et al. Among authors: mehta p. Blood Adv. 2023 Aug 22;7(16):4539-4549. doi: 10.1182/bloodadvances.2023010276. Blood Adv. 2023. PMID: 37171402 Free PMC article. Clinical Trial.
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation.
Iland HJ, Russell N, Dillon R, Schuh AC, Tedjaseputra A, Wei A, Khwaja A, Knapper S, Lane SW, Reynolds J, McMullin MF, Martin A, Tan P, Taussig DC, Wong A, Taper J, Fraga C, Kelly R, Tawana K, Mehta P, Mina A, Altman JK, Mølle I, Tauro S, Tholouli E. Iland HJ, et al. Among authors: mehta p. Blood Adv. 2023 Jun 13;7(11):2580-2585. doi: 10.1182/bloodadvances.2022007126. Blood Adv. 2023. PMID: 36075018 Free PMC article. No abstract available.
Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.
Othus M, Thomas I, Wang X, Ariti C, Mehta P, Sydenham M, Hills RK, Burnett AK, Nand S, Assouline S, Michaelis LC, Erba HP, Russell N, Kerr KF, Walter RB, Dennis M. Othus M, et al. Among authors: mehta p. Leuk Lymphoma. 2023 Jan;64(1):250-252. doi: 10.1080/10428194.2022.2131416. Epub 2022 Oct 13. Leuk Lymphoma. 2023. PMID: 36226777 Free PMC article. No abstract available.
A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial.
Mussai F, De Santo C, Cheng P, Thomas IF, Ariti C, Upton L, Scarpa U, Stavrou V, Sydenham M, Burnett AK, Knapper SK, Mehta P, McMullin MF, Copland M, Russell NH, Dennis M. Mussai F, et al. Among authors: mehta p. Br J Haematol. 2023 Mar;200(5):573-578. doi: 10.1111/bjh.18560. Epub 2022 Nov 22. Br J Haematol. 2023. PMID: 36413792 Free article. Clinical Trial.
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
Freeman SD, Thomas A, Thomas I, Hills RK, Vyas P, Gilkes A, Metzner M, Jakobsen NA, Kennedy A, Moore R, Almuina NM, Burns S, King S, Andrew G, Gallagher KME, Sellar RS, Cahalin P, Weber D, Dennis M, Mehta P, Knapper S, Russell NH. Freeman SD, et al. Among authors: mehta p. Blood. 2023 Nov 16;142(20):1697-1707. doi: 10.1182/blood.2023020630. Blood. 2023. PMID: 37595359 Free PMC article.
2,675 results